Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients.
Sophie LaroumagneJulie TronchettiHervé DutauPhilippe AstoulPublished in: Current oncology (Toronto, Ont.) (2024)
Maintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphotericin B was started. Oncologists should bear in mind that visceral leishmaniasis in endemic areas can potentially induce severe and prolonged pancytopenia in immunosuppressed patients, during chemotherapy in particular.
Keyphrases
- drug induced
- bone marrow
- liver injury
- end stage renal disease
- small cell lung cancer
- multiple sclerosis
- newly diagnosed
- combination therapy
- ejection fraction
- adipose tissue
- chronic kidney disease
- mesenchymal stem cells
- locally advanced
- clinical trial
- squamous cell carcinoma
- radiation therapy
- ultrasound guided
- stem cells
- peritoneal dialysis
- palliative care
- study protocol
- low grade
- patient reported outcomes
- rectal cancer
- cell therapy